Oncolytic Virotherapy

‘In Situ Personalized Tumor Vaccine’

Armed with immune-modulatory payloads to tune tumor microenvironment

OV elicits anti-tumor immunity in the tumor microenvironment through its payloads.
OV alters the immunosuppressed tumor microenvironment through its payloads.
Intratumorally injected OV can trigger systemic anti-tumor response.

Virogin's innovative approaches to
overcome existing challenges of approved OVs

Limitation 1: Attenuated OVs (e.g., through gene deletion) weakens the virus's ability to replicate, resulting in limited clinical benefit.

Solution 1: Transcription & Translation Dual Regulation (TTDR) backbone to enhance viral replication in tumor cells.

üAt transcription level – Based on transcriptional control of the essential HSV-1 immediate-early protein using a tumor-associated promoter which, resulting in enhanced yet selective viral replication in tumors.

üAt translational level – Translational control of the neurovirulence factor ICP34.5 is achieved using multiple microRNA (miR)-binding sites.This miRNA regulation results in excellent safety .

Limitation 2: Currently used payloads have only a weak effect on inducing anti-tumor immune response.

Solution 2: Multiple cytokine payloads synergistically boost innate and adaptive immune responses to promote anti-tumor activity.

Our HSV-1 expressing IL-12, IL-15, IL-15Rα creates a strong immunostimulatory tumor microenvironment that can lead to the destruction of treated and untreated tumors (abscopal effect).